
The centiloid (CL) scale, a tracer-independent metric for amyloid-PET quantification, has been validated by the AMYPAD consortium as a reliable tool for assessing amyloid-β (Aβ) pathology in Alzheimer's disease (AD). A CL value below 10 confidently excludes Aβ pathology, while values above 30 indicate pathological levels. Intermediate values suggest an elevated risk of disease progression. By complementing visual amyloid-PET assessments, CL quantification aids in diagnosing AD, determining eligibility for anti-amyloid therapies, and monitoring amyloid clearance during treatment. This scale provides precision in patient management and therapy optimization, underscoring its critical role in clinical practice.
Like
Save
Share